sur INVENTIVA (EPA:IVA)
Renée Aguiar-Lucander Joins Inventiva's Board of Directors
Inventiva, a biopharmaceutical company, has announced the appointment of Renée Aguiar-Lucander to its Board of Directors. The shareholders approved this addition during the company's recent Annual General Meeting. Mark Pruzanski, Chairman of Inventiva, emphasized Aguiar-Lucander's significant industry experience as the company moves into crucial stages of clinical development.
Renée Aguiar-Lucander, currently CEO of Hansa Biopharma, previously led Calliditas Therapeutics to a successful NASDAQ listing and acquisition by Asahi Kasei. Her leadership secured FDA approval for a unique IgA nephropathy treatment.
Inventiva focuses on developing treatments for metabolic dysfunction-associated steatohepatitis (MASH), with its lead product, lanifibranor, in the Phase 3 trial stage.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de INVENTIVA